Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 29

1.

IRS2 copy number gain, KRAS and BRAF mutation status as predictive biomarkers for response to the IGF-1R/IR inhibitor BMS-754807 in colorectal cancer cell lines.

Huang F, Chang H, Greer A, Hillerman S, Reeves KA, Hurlburt W, Cogswell J, Patel D, Qi Z, Fairchild C, Ryseck RP, Wong TW, Finckenstein FG, Jackson J, Carboni JM.

Mol Cancer Ther. 2015 Feb;14(2):620-30. doi: 10.1158/1535-7163.MCT-14-0794-T. Epub 2014 Dec 19.

2.

Differential mechanisms of acquired resistance to insulin-like growth factor-i receptor antibody therapy or to a small-molecule inhibitor, BMS-754807, in a human rhabdomyosarcoma model.

Huang F, Hurlburt W, Greer A, Reeves KA, Hillerman S, Chang H, Fargnoli J, Graf Finckenstein F, Gottardis MM, Carboni JM.

Cancer Res. 2010 Sep 15;70(18):7221-31. doi: 10.1158/0008-5472.CAN-10-0391. Epub 2010 Aug 31.

3.

Proline isosteres in a series of 2,4-disubstituted pyrrolo[1,2-f][1,2,4]triazine inhibitors of IGF-1R kinase and IR kinase.

Sampognaro AJ, Wittman MD, Carboni JM, Chang C, Greer AF, Hurlburt WW, Sack JS, Vyas DM.

Bioorg Med Chem Lett. 2010 Sep 1;20(17):5027-30. doi: 10.1016/j.bmcl.2010.07.045. Epub 2010 Jul 15.

PMID:
20675137
4.

BMS-754807, a small molecule inhibitor of insulin-like growth factor-1R/IR.

Carboni JM, Wittman M, Yang Z, Lee F, Greer A, Hurlburt W, Hillerman S, Cao C, Cantor GH, Dell-John J, Chen C, Discenza L, Menard K, Li A, Trainor G, Vyas D, Kramer R, Attar RM, Gottardis MM.

Mol Cancer Ther. 2009 Dec;8(12):3341-9. doi: 10.1158/1535-7163.MCT-09-0499.

5.

Discovery of a 2,4-disubstituted pyrrolo[1,2-f][1,2,4]triazine inhibitor (BMS-754807) of insulin-like growth factor receptor (IGF-1R) kinase in clinical development.

Wittman MD, Carboni JM, Yang Z, Lee FY, Antman M, Attar R, Balimane P, Chang C, Chen C, Discenza L, Frennesson D, Gottardis MM, Greer A, Hurlburt W, Johnson W, Langley DR, Li A, Li J, Liu P, Mastalerz H, Mathur A, Menard K, Patel K, Sack J, Sang X, Saulnier M, Smith D, Stefanski K, Trainor G, Velaparthi U, Zhang G, Zimmermann K, Vyas DM.

J Med Chem. 2009 Dec 10;52(23):7360-3. doi: 10.1021/jm900786r.

PMID:
19778024
6.

The mechanisms of differential sensitivity to an insulin-like growth factor-1 receptor inhibitor (BMS-536924) and rationale for combining with EGFR/HER2 inhibitors.

Huang F, Greer A, Hurlburt W, Han X, Hafezi R, Wittenberg GM, Reeves K, Chen J, Robinson D, Li A, Lee FY, Gottardis MM, Clark E, Helman L, Attar RM, Dongre A, Carboni JM.

Cancer Res. 2009 Jan 1;69(1):161-70. doi: 10.1158/0008-5472.CAN-08-0835.

7.

Parallel synthesis of 2-aryl-4-aminobenzimidazoles and their evaluation as gonadotropin releasing hormone antagonists.

Green DM, Goljer I, Andraka DS, Chengalvala M, Shanno L, Hurlburt W, Pelletier JC.

J Comb Chem. 2009 Jan-Feb;11(1):117-25. doi: 10.1021/cc800106h.

PMID:
19049392
8.

Discovery and evaluation of 4-(2-(4-chloro-1H-pyrazol-1-yl)ethylamino)-3-(6-(1-(3-fluoropropyl)piperidin-4-yl)-4-methyl-1H-benzo[d]imidazol-2-yl)pyridin-2(1H)-one (BMS-695735), an orally efficacious inhibitor of insulin-like growth factor-1 receptor kinase with broad spectrum in vivo antitumor activity.

Velaparthi U, Wittman M, Liu P, Carboni JM, Lee FY, Attar R, Balimane P, Clarke W, Sinz MW, Hurlburt W, Patel K, Discenza L, Kim S, Gottardis M, Greer A, Li A, Saulnier M, Yang Z, Zimmermann K, Trainor G, Vyas D.

J Med Chem. 2008 Oct 9;51(19):5897-900. doi: 10.1021/jm800832q. Epub 2008 Sep 3.

PMID:
18763755
9.

Linitis plastica in a 16-year-old. 1975.

Hurlburt WB.

Alaska Med. 2006 Jul-Sep;48(2):64-6.

PMID:
17140154
10.

Discovery of a (1H-benzoimidazol-2-yl)-1H-pyridin-2-one (BMS-536924) inhibitor of insulin-like growth factor I receptor kinase with in vivo antitumor activity.

Wittman M, Carboni J, Attar R, Balasubramanian B, Balimane P, Brassil P, Beaulieu F, Chang C, Clarke W, Dell J, Eummer J, Frennesson D, Gottardis M, Greer A, Hansel S, Hurlburt W, Jacobson B, Krishnananthan S, Lee FY, Li A, Lin TA, Liu P, Ouellet C, Sang X, Saulnier MG, Stoffan K, Sun Y, Velaparthi U, Wong H, Yang Z, Zimmermann K, Zoeckler M, Vyas D.

J Med Chem. 2005 Sep 8;48(18):5639-43.

PMID:
16134929
11.

Tumor development by transgenic expression of a constitutively active insulin-like growth factor I receptor.

Carboni JM, Lee AV, Hadsell DL, Rowley BR, Lee FY, Bol DK, Camuso AE, Gottardis M, Greer AF, Ho CP, Hurlburt W, Li A, Saulnier M, Velaparthi U, Wang C, Wen ML, Westhouse RA, Wittman M, Zimmermann K, Rupnow BA, Wong TW.

Cancer Res. 2005 May 1;65(9):3781-7.

12.

Biochemical characterization of osteo-testicular protein tyrosine phosphatase and its functional significance in rat primary osteoblasts.

Chengalvala MV, Bapat AR, Hurlburt WW, Kostek B, Gonder DS, Mastroeni RA, Frail DE.

Biochemistry. 2001 Jan 23;40(3):814-21.

PMID:
11170399
14.

Characterization of monoclonal antibodies recognizing amino- and carboxy-terminal epitopes of the herpes simplex virus UL42 protein.

Sheaffer AK, Hurlburt WW, Stevens JT, Bifano M, Hamatake RK, Colonno RJ, Tenney DJ.

Virus Res. 1995 Oct;38(2-3):305-14.

PMID:
8578868
15.

The C-terminal 25 amino acids of the protease and its substrate ICP35 of herpes simplex virus type 1 are involved in the formation of sealed capsids.

Matusick-Kumar L, Newcomb WW, Brown JC, McCann PJ 3rd, Hurlburt W, Weinheimer SP, Gao M.

J Virol. 1995 Jul;69(7):4347-56.

16.

Sequence-dependent primer synthesis by the herpes simplex virus helicase-primase complex.

Tenney DJ, Sheaffer AK, Hurlburt WW, Bifano M, Hamatake RK.

J Biol Chem. 1995 Apr 21;270(16):9129-36.

17.

Phenotype of the herpes simplex virus type 1 protease substrate ICP35 mutant virus.

Matusick-Kumar L, Hurlburt W, Weinheimer SP, Newcomb WW, Brown JC, Gao M.

J Virol. 1994 Sep;68(9):5384-94.

18.

The protease of herpes simplex virus type 1 is essential for functional capsid formation and viral growth.

Gao M, Matusick-Kumar L, Hurlburt W, DiTusa SF, Newcomb WW, Brown JC, McCann PJ 3rd, Deckman I, Colonno RJ.

J Virol. 1994 Jun;68(6):3702-12.

19.
20.

The herpes simplex virus type 1 DNA polymerase accessory protein, UL42, contains a functional protease-resistant domain.

Hamatake RK, Bifano M, Tenney DJ, Hurlburt WW, Cordingley MG.

J Gen Virol. 1993 Oct;74 ( Pt 10):2181-9.

PMID:
8409941
21.

Deletions of the carboxy terminus of herpes simplex virus type 1 UL42 define a conserved amino-terminal functional domain.

Tenney DJ, Hurlburt WW, Bifano M, Stevens JT, Micheletti PA, Hamatake RK, Cordingley MG.

J Virol. 1993 Apr;67(4):1959-66.

22.

Mutations in the C terminus of herpes simplex virus type 1 DNA polymerase can affect binding and stimulation by its accessory protein UL42 without affecting basal polymerase activity.

Tenney DJ, Micheletti PA, Stevens JT, Hamatake RK, Matthews JT, Sanchez AR, Hurlburt WW, Bifano M, Cordingley MG.

J Virol. 1993 Jan;67(1):543-7.

23.

The Indian Health Service record of achievement.

Rhoades ER, D'Angelo AJ, Hurlburt WB.

Public Health Rep. 1987 Jul-Aug;102(4):356-60.

24.

Cancer incidence in Alaska natives.

Lanier AP, Bender TR, Blot WJ, Fraumeni JF Jr, Hurlburt WB.

Int J Cancer. 1976 Oct 15;18(4):409-12.

PMID:
977187
25.

Linitis plastica in a 16-year-old.

Hurlburt WB.

Alaska Med. 1975 Sep;17(5):77-9. No abstract available.

PMID:
171966
26.

Health care programs for scattered populations.

Hurlburt WB.

Public Health Rev. 1975 Jul-Dec;4(3-4):297-325.

PMID:
10246984
27.

Spontaneous intrathoracic lymphocyst.

Hurlburt WB.

Am Rev Respir Dis. 1972 Feb;105(2):283-6. No abstract available.

PMID:
5009805
28.

Selective blind catheterization of the main bronchi.

Hurlburt WB.

Radiology. 1971 Dec;101(3):510. No abstract available.

PMID:
5129091
29.

Carcinoma of the bladder.

Hurlburt WB.

Am Fam Physician GP. 1970 Nov;2(5):109-13. No abstract available.

PMID:
5274321

Supplemental Content

Loading ...
Support Center